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Abstract The pituitary adenylate cyclase activating polypeptide
(PACAP) type I receptor belongs to the glucagon/secretin/
vasoactive intestinal polypeptide (VIP) receptor family. We
mutated and deleted an amino acid residue (E261) which is
located within the second intracellular loop of the rat PACAP
type I receptor and which is highly conserved among the receptor
family. The wild-type receptor and the mutant receptors were
efficiently expressed at the surface of COS-7 cells at nearly the
same level and revealed the same high affinity for the agonist
PACAP-27. The cAMP contents of COS cells transfected with
the E261A, E261Q, and the deletion mutant receptor were 4.6-,
5.7-, and 6.7-fold higher as compared with COS cells transfected
with the wild-type receptor. Thus, all the mutant PACAP
receptors were constitutively active. The data suggest that the
glutamic acid in the second intracellular loop of the PACAP
receptor may be a key residue to constrain the receptor in the
inactive conformation with respect to its coupling to Gs proteins.
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1. Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP)
is a neuropeptide originally isolated from ovine hypothalamic
tissue [1]. PACAP is one of most potent stimulators of the
adenylate cyclase and exists in two forms: PACAP-38 with 38
amino acids and PACAP-27 corresponding to the N-terminal
27 residues of PACAP-38. Both forms were found to be equi-
potent in receptor binding and adenylate cyclase assays [2].
PACAP is widely distributed in mammalians with the highest
concentration in the central nervous system [3]. It is a hypo-
physiotropic hormone and also functions as neurotransmitter,
neuromodulator and neurotrophic factor in the central nerv-
ous system [4,5].
Three PACAP receptor types have been pharmacologically
characterized. The type I receptor is distributed mainly in the
central nervous system and has a high a⁄nity for PACAP,
but a 1000-fold lower a⁄nity for VIP [6]. In contrast, the type
II and III receptors which are widely distributed in peripheral
tissues recognize PACAP and VIP with similar a⁄nities and
are therefore identical with the VIP receptors. It has been
recommended to use the terms PAC1 for type I receptor,
VPAC1 for type II receptor and VPAC2 for type III receptor
[7].
PACAP receptors belong to a new protein subfamily within
the seven-transmembrane domain G protein coupled receptor
(GPCR) superfamily [8^12]. This family, now referred to as
class II GPCRs, includes, among others, receptors for secre-
tin, glucagon, glucagon-like peptide 1, growth hormone re-
leasing hormone, gastric inhibitory peptide, parathyroid hor-
mone and calcitonin [13]. The receptors of this family all
couple primarily to Gs to stimulate adenylate cyclase. How-
ever, the putative intracellular receptor domains which are
involved in G protein interaction have not been de¢ned. Se-
quence alignment analysis shows a glutamic acid in the puta-
tive center of the second intracellular loop which is highly
conserved among the various receptors of the class II GPCRs
(Fig. 1). This prompted us to test whether this residue plays a
crucial role for G protein coupling and signal transduction.
We have constructed several Glu-261 mutants of the rat
PAC1 receptor and studied its functional role in G protein
activation. The results show that all mutations at this position
lead to constitutive active PACAP receptors. Hence, this glu-
tamic acid may be involved in stabilizing the PAC1 receptor
in an inactivated state which does not allow the receptor to
bind to Gs proteins.
2. Materials and methods
2.1. Materials
125I-labeled goat anti-mouse immunoglobulin G and 125I-PACAP-
27 were from NEN (Ko«ln, Germany). PACAP-27 was from Novabio-
chem (Bad Soden, Germany). Soybean trypsin inhibitor and BSA
were from Serva (Heidelberg, Germany). All other chemicals and
culture media were purchased from Sigma (Deisenhofen, Germany).
2.2. Construction of mutant receptors
The construction of the expression plasmid pPACAPR was per-
formed as previously described [14]. This plasmid encodes an ami-
no-terminal c-myc epitope tag and the full-length rat PAC1 receptor.
Oligonucleotide-directed mutagenesis was performed by in vitro muta-
genesis. The EcoRI/XbaI fragment encoding the c-myc tagged full-
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length type I receptor cDNA was subcloned into the multiple cloning
site of the mutagenesis vector pAlter1 (Promega). Single strand DNA
was prepared. To create the mutants, the nucleotide sequence encod-
ing the amino acid Glu, was deleted or exchanged by Ala or Gln. For
this purpose, oligonucleotides which each introduce a unique restric-
tion site were used: original coding nucleotide sequence, 5P-GAG
ACC TTC TTC CCT GAG AGG AGA TAT TTC TAC T-3P ; oligo-
nucleotide for deletion mutation with ArvII sequence underlined, 5P-
GAG ACC TTC TTC CCT AGG AGA TAT TTC TAC T-3P ; oli-
gonucleotide for E261A exchange with BssHII sequence underlined,
5P-GAG ACC TTC TTC CCT GCG CGC AGA TAT TTC TAC
T-3P ; oligonucleotide for E261Q exchange with BsmBI sequence
underlined, 5P-GAG ACC TTC TTC CCT CAG AGA CGA TAT
TTC TAC T-3P. The vectors containing the PAC1 receptor mutant
constructs were transformed into DH5K using ampicillin and tetracy-
clin selection. The mutant cDNAs were subcloned into the BamHI
and HpaI sites of the pPACAP plasmid and the mutations were con-
¢rmed by dideoxy DNA sequencing.
2.3. Cell culture and transient transfection
Hybridoma cells producing the anti-c-myc monoclonal antibody
9E10 were cultivated as described [14]. The hybridoma supernatant
was used undiluted as antibody source for the subsequent immuno-
detection procedures. COS-7 cells were grown in 100 mm petri dishes
or 24-well plates using DMEM containing 10% fetal calf serum at
37‡C. For transient transfection of COS-7 cells, we used a modi¢ed
DEAE-dextran/chloroquine method as previously described [15].
2.4. Membrane preparation
COS-7 cells were harvested about 60 h after the transfection by
scraping with phosphate bu¡ered saline (PBS) containing 1 mM
EDTA. The cell pellets were suspended in bu¡er A (5 mM HEPES,
pH 7.4, 1 mM EDTA) and homogenized using a Elvjehm homoge-
nizer. The homogenate was centrifuged at 40 000Ug for 20 min. The
pellet was resuspended in bu¡er B (20 mM HEPES, pH 7.4, 1 mM
EDTA, 0.5 mM PMSF, 0.1 mg/ml bacitracin, 0.1 mg/ml soybean
trypsin inhibitor, 5 Wg/ml antipain, 5 Wg/ml leupeptin and 1 Wg/ml
pepstatin) and was then recentrifuged. The membrane pellet was re-
suspended at a protein concentration of 2^5 mg/ml in bu¡er B. The
designated membrane fragments were frozen in aliquots and stored at
370‡C. Protein content was quanti¢ed by the Bradford method using
BSA as a standard.
2.5. Receptor binding studies
Binding experiments were performed as previously described [16].
Brie£y, competitive binding assays were carried out with membranes
containing PAC1 receptors or its mutants with 125I-PACAP-27 and
various amounts of PACAP-27 at 25‡C for 40 min in binding bu¡er
(20 mM HEPES, pH 7.4, 1 mM MgCl2, 1 mM EGTA, 0.5% BSA,
0.5 mg/ml bacitracin, 0.04 mg/ml soybean trypsin inhibitor, 1 mM
PMSF). Non-speci¢c binding was determined by incubation in the
presence of a 1000-fold excess of unlabeled PACAP-27. This value
was subtracted from total binding to yield the speci¢c PACAP bind-
ing.
2.6. Intracellular cAMP assay
About 24 h after transfection, the COS-7 cells were transferred to
24-well culture plates (V1U105 cells/well) and were grown for further
36 h. The cells were rinsed with assay solution (Hanks’ balanced salt
solution (HBSS) containing 0.1% BSA) and were incubated for 30 min
at 37‡C in the absence or presence of increasing concentrations of
PACAP-27. A concentration of 1 mM of 3-isobutylmethylxanthine
was present in the assay solution. Reactions were terminated by aspi-
rating the medium, washing the cells with HBSS and adding 0.24 ml
of ice-cold 5% trichloroacetic acid. Intracellular accumulation of
cAMP was determined using the Amersham kit (TRK 432), as de-
scribed previously [17].
2.7. Evaluation of receptor cell surface expression
Wild-type or mutant PAC1 receptors contain the myc epitope at the
N-terminus and thus, if correctly expressed, expose the epitope at the
extracellular surface of transfected COS-7 cells. The cells were rinsed
three times with PBS (pH 7.4) containing 5% FBS in a 24-well plate.
They were then incubated with the hybridoma supernatant of the anti-
myc monoclonal antibody 9E10 at 15‡C for 2 h. The cells were
washed four times before adding 125I-labeled goat anti-mouse immu-
noglobulin G (1:500). After 2 h at room temperature, the incubation
was terminated by washing four times with the same bu¡er and the
cells were lysed with 5 N NaOH. The radioactivity was counted in the
gamma spectrometer.
2.8. Analysis of data
Results are expressed as means þ S.E.M. All experiments were done
at least twice and each determination was done in triplicate. The LI-
GAND computer program (Biosoft) was used for the mathematical
analysis of the binding data. Figures and curve ¢ts were drawn using
the SigmaPlot software package (Jandel Scienti¢c).
3. Results
3.1. Construction and expression of the Glu-261 mutants of
PAC1 receptor
As indicated in Fig. 1, a highly conserved glutamic acid
(E261 in rat PAC1 receptor) is found within the second intra-
cellular loop of the glucagon/secretin/VIP receptor family. To
evaluate a potential interaction of this glutamic acid with G
proteins, we performed site-directed mutagenesis at this posi-
tion. Three mutant PAC1 receptors were created: E261 was
deleted or exchanged by Gln or Ala, referred to as ‘DEL’,
‘EQ’, and ‘EA’ mutants. The constructs which encode PAC1
wild-type and mutant receptors were expressed in COS-7 cells.
Each of the constructs encodes a myc epitope (EQLISEEDL)
at the N-terminus of the receptor which was exploited to
assess receptor surface expression in intact COS cells. Fig. 2
shows that the wild-type receptor as well as the three mutant
Fig. 1. Sequence alignment of the second intracellular loop of class
II GPCRs. The glutamic acid (E261, outlined in black) of the rat
PAC1 receptor was mutated in this study.
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receptors were e⁄ciently expressed at nearly the same level on
the surface of the cells.
3.2. Ligand binding a⁄nity of the Glu-261 mutants of PAC1
receptor
To characterize the expressed PAC1 receptors in mem-
branes of transfected COS cells, competitive binding experi-
ments were performed using 125I-PACAP-27 as radioligand
and increasing amounts of PACAP-27 as homologous dis-
placer. As shown in Fig. 3, the doses of unlabeled PACAP-
27 required to produce half-maximal inhibition (IC50) of
125I-PACAP-27 binding activity were 0.79 nM for the wild-
type PAC1 receptor, 0.69 nM for the EQ mutant, 0.94 nM for
the EA mutant, and 0.84 nM for the DEL mutant. The statis-
tical evaluation of the ¢tted data revealed that the calculated
IC50 values for the three mutant receptors were not signi¢-
cantly di¡erent from the IC50 value calculated for the wild-
type PAC1 receptor. In case of the ¢tted data for the mutants
EA and EQ, slightly shallower displacement curves (see slope
factors in the legend of Fig. 3) were obtained. This prompted
us to test for the potential presence of two or more a⁄nity
states in case of these two mutants. However, even in experi-
ments with more data points, a one-site ¢t was always signi¢-
cantly better than a two- or more-site ¢t (not shown). Overall,
these results demonstrate that the ligand binding a⁄nities of
the mutant PAC1 receptors were not signi¢cantly a¡ected as
compared to the wild-type PAC1 receptor.
3.3. Intracellular cAMP production of the Glu-261 mutants in
COS cells
Next, we determined whether the E261 mutations in the
second intracellular loop of the PAC1 receptor in£uence the
stimulation of the adenylate cyclase. For that purpose, the
intracellular cAMP production was measured in COS cells
transfected with the wild-type or the mutant receptors follow-
ing stimulation with PACAP-27 in the presence of isobutyl-
methylxanthine. Using 0.1 WM PACAP-27, the same maximal
intracellular cAMP content was produced in COS cells ex-
pressing either wild-type or mutant PAC1 receptors. In case
of the wild-type receptor, the PACAP-27-induced cAMP level
was 38-fold higher than the basal, i.e. uninduced cAMP level
of the cells.
Fig. 4 shows the dose^response curves for the wild-type and
mutant receptors with respect to the intracellular cAMP pro-
duction in dependence of various PACAP-27 concentrations.
For COS cells transfected with the wild-type receptor, half-
maximal stimulation (EC50) of cAMP production was ob-
tained with 1.64 nM PACAP-27. The corresponding EC50
values for the mutant receptors are given in the legend to
Fig. 4. In COS cells transfected with the EA and DEL mutant
receptors, slightly higher (1.7- and 3-fold) concentrations of
PACAP-27 were necessary to achieve half-maximal stimula-
tion of the intracellular cAMP level. Overall, the EC50 values
(Fig. 4) for the PACAP-27 activation of the wild-type and
Fig. 2. Surface expression of the wild-type and mutant PAC1 recep-
tors in transfected COS-7 cells. Anti-myc monoclonal antibody
(9E10) binding to myc epitope tagged receptors was used to quanti-
tate the levels of receptors expressed at the cell surface. Mock-trans-
fected COS-7 cells were used as control, i.e. basal binding of the
antibody. Data shown are the means þ S.D. of three measurements
performed in triplicate. WT, wild-type receptor; EQ and EA, E261
substituted by Q and A; DEL, E261 deletion mutation.
Fig. 3. Competition binding isotherms of 125I-PACAP-27 by PA-
CAP-27 in membranes of COS-7 cells transfected with the PAC1
wild-type receptor (closed circle) and the receptor mutants E261Q
(open circle), E261A (closed square) and E261 deletion mutant
(open square). Membranes (40 Wg/ml) were incubated with 0.1 nM
125I-PACAP-27 and increasing concentrations of PACAP-27 in a ¢-
nal volume of 0.1 ml. Binding is expressed as the percentage of spe-
ci¢c binding obtained in the absence of the competitor PACAP-27.
The IC50 values and slope factors of the ¢tted curves were as fol-
lows: 0.79 nM and 1.76 (closed circle), 0.69 nM and 0.88 (open
circle), 0.94 nM and 1.12 (closed square), 0.84 nM and 1.65 (open
square).
Fig. 4. Ability of PACAP-27 to increase intracellular cAMP in
COS-7 cells expressing rat PAC1 wild-type (closed circle) and mu-
tant receptors E261Q (open circle), E261A (closed square) and E261
deletion mutant (open square). The cells were incubated with in-
creasing concentrations of PACAP-27 at 37‡C for 30 min (for de-
tails see Section 2.6). The produced cAMP accumulations are pre-
sented as percentage of the maximal stimulation level. The data
represent averages of three determinations. The corresponding EC50
values were 1.6 nM (closed circle), 1.7 nM (open circle), 2.9 nM
(closed square), and 5.0 nM (open square).
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mutant PAC1 receptors are in good agreement with the cor-
responding IC50 values (Fig. 3) that were obtained in the
competition binding assays.
3.4. The Glu-261 mutants are constitutively active PAC1
receptors
While the agonist-induced activation of the mutant PAC1
receptors lead to the same level of cAMP signal transduction,
an unexpected discrepant behavior of the mutants versus wild-
type receptor was observed when the ligand-independent
cAMP production was analyzed. The basal levels of cAMP
accumulation were substantially higher in COS cells trans-
fected with the mutant PAC1 receptors as compared with
COS cells transfected with either the wild-type receptor or
with mock-transfected cells. In comparison with COS cells
expressing the wild-type receptor, the basal cAMP levels
were found to be 5.7-, 4.6- and 6.7-fold higher in cells express-
ing the EQ, EA and DEL mutant receptor, respectively (Fig.
5). These observations show that each of the E261 mutations
changes the PAC1 receptor into a ligand-independent consti-
tutively active receptor.
4. Discussion
It is known that the intracellular domains of the GPCRs
are involved in G protein recognition and activation [18]. For
the class II GPCR family, only few studies have been per-
formed to identify G protein interacting domains. Deletion
mutants in the third intracellular loop of the glucagon-like
peptide 1 receptor resulted in a dramatic reduction of ago-
nist-stimulated cAMP production, suggesting that this region
may contain key residues involved in G protein contact [19].
Di¡erential signal transduction has been reported for the
PAC1 receptor. There are two alternatively spliced exons in
the PAC1 receptor gene, rat hip and hop [8] or human SV-1
and SV-2 [20]. This results in the existence of splice variants of
the PAC1 receptor which di¡er in the length of the third
intracellular loop. A hip cassette inserting in the third intra-
cellular loop of the rat PAC1 receptor impairs adenylate cy-
clase stimulation and abolishes phospholipase C stimulation
[8]. This suggests that the third intracellular loop is an impor-
tant determinant, at least in coupling of the rat PAC1 recep-
tor to phospholipase C activating G proteins. On the other
hand, for each of the human PAC1 receptor splice variants,
PACAP-27 had similar a⁄nity and potency to stimulate either
adenylate cyclase or phospholipase C [20]. Thus, further do-
mains seem to be required for coupling of the PAC1 receptor
to adenylate cyclase stimulating Gs proteins. Our data show
that the mutagenesis of a glutamic acid (E261) within the
second intracellular loop of the rat PAC1 receptor results in
constitutively active receptors. Thus, the mutant PAC1 recep-
tors adopted one or more conformations that enable them to
bind to Gs proteins which in turn stimulate the adenylate
cyclase. This suggests but does not prove that the second
intracellular loop is involved in cAMP signaling. The impor-
tance of the second intracellular loop for Gs coupling has also
been demonstrated for another member of the class II
GPCRs, the glucagon receptor [21]. Deletion of eight residues
within the putative second intracellular loop of the human
glucagon receptor resulted in a protein that was well expressed
showing a high a⁄nity for glucagon but a drastically attenu-
ated glucagon-mediated signal activation [21].
Constitutively active class II receptors resulted from histi-
dine to arginine exchanges at a conserved position localized in
the ¢rst intracellular loop of the human VIP1 ( = VPAC1) [22]
receptor, the glucagon receptor [23] and the PTH-PTHrP re-
ceptor [24]. A rare form of short-limbed dwar¢sm, the Jansen-
type metaphyseal chondrodysplasia, was found to be associ-
ated with the latter constitutively active PTH-PTHrP receptor
[24]. For both the VIP1 and glucagon receptor, the replace-
ment of this histidine by residues other than arginine did not
lead to constitutive receptor activity but instead to a loss of
ligand binding activity and cAMP production for the VIP1
receptor [22] and to an increased binding a⁄nity for the glu-
cagon receptor [23]. Hence, the constitutively active receptor
phenotype created by the histidine to arginine substitution is
clearly di¡erent from the mutant PAC1 receptor phenotype
described in this study. There is now compelling evidence that
the mechanisms by which constitutive receptor activities are
generated, can di¡er among GPCRs. In case of the K1b-ad-
renergic receptor, all possible mutations at a single position
within the third intracellular loop confer constitutive receptor
activity in conjunction with a higher a⁄nity for agonists [25],
a behavior which was ¢rst thought to be typical for constitu-
tively active receptors. Since then, several other constitutively
active receptor mutants were described which did not show a
higher agonist a⁄nity, such as the receptors for thyrotropin
[26], luteinizing hormone [27], angiotensin 1A [28], or oxyto-
cin [29].
Conclusively, in this report, we have identi¢ed the ¢rst con-
stitutively active PAC1 receptor. The mutated glutamic acid
residue is highly conserved within the second intracellular
loop of class II GPCRs and may thus be of importance for
many members of this receptor class. Since the glutamic acid
residue is also present in the human PAC1 receptor and muta-
genesis of this residue leads to a strong basal adenylate cyclase
activity, humans with naturally occurring mutations at the
equivalent position may have severe pathophysiological symp-
toms.
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